A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV vaccine in healthy participants aged 18-40 years or in participants aged 18-60 years with recurrent HSV-2 genital herpes - TH HSV REC-003

GlaxoSmithKline, S.A.0 个研究点目标入组 332 人开始时间: 2022年4月25日最近更新: 2022年8月8日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: GlaxoSmithKline, S.A.
入组人数: 332

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Participants, who, in the opinion of the investigator, can and will comply with the requirements of the Protocol.
•Written informed consent obtained from the participant prior to performance of any study-specific procedure.
•Women of non-childbearing potential may be enrolled in the study.
•Women of childbearing potential may be enrolled in the study, if the participant:
•- Has practiced highly effective contraception for one month prior to study intervention administration, and,
•- Has a negative pregnancy test result at the Screening visit and on the day of each study intervention administration, and,
•- Has agreed to continue highly effective contraception until the end of the study.
•Seronegative for human immunodeficiency virus (HIV), as determined by laboratory screening tests. Participants documented to be seropositive to HIV will not be eligible for study participation.
•Only for PART I: Healthy participants as established by medical history and physical examination, at the discretion of the investigator, before entering into the study.
•Only for PART I: Man or woman aged 18 to 40 years, included, at the time of the first study intervention administration.
•Only for PART I: Seronegative for HSV-2 as determined by Western blot performed at the Screening visit.
•Only for PART II: Participants with recurrent HSV-2 genital herpes and with no significant health problems as established by medical history and physical examination, at the discretion of the investigator, before entering the study.
•- Diagnosis of genital HSV-2 infection for at least one year before the Screening visit.
•- History of recurrent genital herpes defined as at least 3 and no more than 9 reported clinical recurrences in the 12 months preceding the screening visit, or, if currently on suppressive therapy, prior to initiation of suppressive therapy.
•Only for PART II: Man or woman aged 18 to 60 years, included, at the time of the first study intervention administration.
•Only for PART II: Seropositive for HSV-2 as determined by Western blot performed at the Screening visit.
•Only for PART II: Participants agreeing to collect 2 swabs per day from anogenital area for the full duration of the 4 swabbing periods planned in the study.
•Only for PART II after baseline completion: Participants having collected at least 45 out of 56 anogenital swabs during the baseline period.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 332
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Medical Conditions
•Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, endocrine, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
•Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study or that would interfere with the efficacy and immunogenicity assessments planned in this study.
•History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention.
•Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
•Hypersensitivity to latex.
•Recurrent history or uncontrolled neurological disorders or seizures.
•Haematological and/or biochemical parameters outside the normal laboratory ranges at the Screening visit, unless the laboratory abnormalities are considered not clinically significant by the investigator.
•Body mass index = 18 kg/m^2 or = 35 kg/m^2.
•History of any form of ocular HSV infection, HSV-related erythema multiforme, or HSV-related neurological complications.
•Participants with symptoms suggestive of coronavirus disease 2019 (COVID-19) infection within 14 days before the first study intervention administration. Participants should be free of symptoms for at least 14 days.
•Participants with known COVID-19-positive contacts in the past 14 days before the first study intervention administration.
•Only for PART II: History of laboratory-confirmed genital HSV-1 infection.
•Prior/Concomitant Therapy
•Use of any investigational or non-registered product other than the study intervention during the period beginning as of the Screening visit, or planned use during the study period.
•Planned administration/administration of a vaccine not foreseen by the Protocol in the period starting 15 days before each dose and ending 15 days after each dose of study intervention administration.
•Administration or planned administration of long-acting immune-modifying drugs at any time during the study period.
•Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first dose of study intervention or planned administration during the study period.
•Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose. For corticosteroids, this will mean prednisone equivalent = 20 mg/day, or equivalent. Inhaled, intra articular and topical steroids are allowed.
•Prior receipt of another vaccine containing HSV antigens.
•Only for PART II: Planned use of suppressive anti-HSV therapy from the Screening visit until the end of the study.
•Only for PART II: Planned use of tenofovir therapy, or other medication known to affect HSV shedding or genital lesions from the Screening visit until the end of the study.
•Only for PART II: Planned use of topical antiviral medication in the anogenital region from the Screening visit until the end of the study.
•Only for PART II: Planned use of any episodic antiviral medications during the 4 anogenital swabbing periods and during the first genital herpes recurrence occurring after administration of the 2 doses of the study intervention.
•Prior/Concurrent Clinical Study Experience
•Concurrently participating in another clinical study, at any time during the stu

研究者

发起方

GlaxoSmithKline, S.A.

相似试验

进行中（未招募）

1 期

EUCTR2021-003586-35-DEGlaxoSmithKline Biologicals SA485

招募中

1 期

EUCTR2021-003586-35-EEGlaxoSmithKline Biologicals SA511

进行中（未招募）

1 期

EUCTR2021-003586-35-BEGlaxoSmithKline Biologicals SA511

进行中（未招募）

1 期

Safety, immunogenicity and efficacy of GSK S.aureus candidate vaccine (GSK3878858A) whenadministered to healthy adults (dose-escalation) andto adults 18 to 64 years of age with a recent S.aureus skin and soft tissue infection (SSTI).

CTRI/2022/07/043738GlaxoSmithKline Biologicals SA

进行中（未招募）

1 期

CTIS2024-510571-37-00GlaxoSmithKline Biologicals515